zilovertamab,ibrutinib
oncternal therapeutics,janssen,abbvie
['zilovertamab', 'ibru', 'oncternal', '$onct']
#oncternaltherapeutics presents rationale and plans for its registrational phase 3 study evaluating #zilovertamab in combination with #ibrutinib at the #eha22 congress $onct 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.